Bayer Corp

XOMA is among the leaders in the discovery, development and manufacture of therapeutic antibodies. The company s broad technology platform, scientific expertise and integrated product development infrastructure extends from antibody discovery to regulatory approval. It is a proven development partner and technology licensor, receiving royalties from Genentech for Raptiva and Lucentis. XOMA s pipeline includes an expanding number of proprietary products and collaborative programs at various stages of clinical and preclinical development. The company s operational infrastructure enables it to produce product candidates in compliance with cGMP using mammalian and microbial systems for preclinical and clinical purposes to meet the needs of many product development programs. Its additional capabilities include cell line development, process and assay creation, contract manufacturing and regulatory compliance. XOMA has operated for more than 25 years and has a location in Berkeley, Calif.

Dynavax Technologies Corporation was founded in August 1996. The company discovers, develops and intends to commercialize products to treat and prevent allergies, infectious diseases and chronic inflammatory diseases, using proprietary approaches that alter immune system responses in specific ways. Its clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Dynavax s pipeline includes: TOLAMBA, a ragweed allergy immunotherapeutic, which has completed a large-scale Phase 2/3 clinical trial, and is in a supportive clinical trial in ragweed allergic children; HEPLISAV, a hepatitis B vaccine that is in a pivotal Phase 3 clinical trial; a cancer therapy in a Phase 2 clinical trial; and an asthma immunotherapeutic that has shown preliminary safety and pharmacologic activity in a Phase 2a clinical trial.